myasthenia%20gravis
MYASTHENIA GRAVIS
Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies against the acetylcholine receptor or against a receptor-associated protein, muscle-specific tyrosine kinase (MuSK-Ab).
The autoimmune attack at the muscle endplate leads to failure of neuromuscular transmission and eventually muscle weakness.
In the active phase of the disease, symptoms typically fluctuates and then become severe; myasthenic crisis occur in this phase.
In the stable/inactive phase, symptoms are stable but still persist; it usually worsen attributable to infection, fatigue, tapering of medications or other identifiable factors.
In the burnt-out phase, remission may occur wherein patients are on immunotherapy and symptom-free, or may even be off medications.
In 15-20 years, if the symptoms left untreated, patient's weakness becomes fixed wherein the most severely affected muscles become atrophic.
Drug Information

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

Indication: Prophylaxis of acute organ rejection in patients receiving allogeneic renal, cardiac & hepatic transplants...

Indication: Immunosuppressant antimetabolite, organ transplants, autoimmune chronic active hepatitis, severe RA, SLE, chro...

Indication: In combination w/ ciclosporin microemulsion & corticosteroids, for the prophylaxis of acute transplant rej...

Indication: Allergic, collagen, dermatological, GI, desquamative gingivitis, hematologic, tuberculous meningitis, ophth, r...

Indication: Bronchial asthma, allergic disease, RA, juvenile RA, rheumatoid myocarditis, rheumatic myelitis, psoriasis, os...

Indication: Transplantation: Solid organ transplantation (kidney, liver, heart, combined heart-lung, lung, pancreas); bone...

1  /  2
Editor's Recommendations
Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.